Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 4.6% on Thursday . The stock traded as low as $21.90 and last traded at $21.63. Approximately 10,387 shares traded hands during trading, a decline of 97% from the average daily volume of 310,105 shares. The stock had previously closed at $22.66.

Analysts Set New Price Targets

Several brokerages recently issued reports on DNTH. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Oppenheimer upped their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Finally, TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Down 4.5 %

The firm has a market cap of $640.40 million, a P/E ratio of -8.62 and a beta of 1.74. The firm’s 50-day simple moving average is $23.27 and its 200 day simple moving average is $26.31.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DNTH. Janus Henderson Group PLC boosted its holdings in shares of Dianthus Therapeutics by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after purchasing an additional 273,670 shares in the last quarter. State Street Corp lifted its position in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares during the last quarter. Braidwell LP boosted its stake in Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares in the last quarter. Point72 Asset Management L.P. grew its position in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after acquiring an additional 263,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after acquiring an additional 97,362 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.